JP Morgan Chase’s Alaunos Therapeutics TCRT Stock Holding History

JP Morgan Chase’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,518	Closed	-$893K	–	5693
2018 Q1	$893K	Buy	+1,518	New	+$946K	﹤0.01%	3736

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

JP Morgan Chase's TCRT Position: Q3 2025 in Review

JP Morgan Chase sold out of Alaunos Therapeutics (TCRT) in Q3 2025, closing a stake of 3 shares — an estimated $15 sold.

JP Morgan Chase first reported a position in TCRT in Q2 2013 and held it in 36 quarters. The position peaked at $18.9M in Q1 2021. 26 funds tracked by Wall St. Rank hold TCRT as of Q3 2025.

JP Morgan Chase reported no remaining Alaunos Therapeutics position as of Q3 2025 after selling out during the quarter.
JP Morgan Chase sold 3 Alaunos Therapeutics shares in Q3 2025, an estimated $15.
JP Morgan Chase first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 36 quarters.
JP Morgan Chase's Alaunos Therapeutics position peaked at $18.9M in Q1 2021.
26 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.